HONG KONG – Chinese vaccine developer Cansino Biologics Inc. is on its way to becoming the seventh pre-revenue biotech to list in Hong Kong. Expected to debut on the main board of the Hong Kong Stock Exchange (HKEX) on March 28, Cansino aims to raise up to HK$1.26 billion (US$160.5 million). Read More
SINGAPORE – For David Lane, chief scientist at the Agency for Science, Technology and Research (A*STAR), it is clear what is required for driving innovation in Asia. Read More
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier. Read More
The innate immune protein NLRP6, which plays a protective role in inflammatory bowel disease (IBD), appears to aggravate intestinal graft-vs.-host disease (GVHD). Read More
HONG KONG – Seoul, South Korea-based SN Bioscience Inc. has developed a drug delivery technology to make injecting antitumor drugs into human bodies possible. Two months after it secured KRW5 billion (US$4.4 million) from South Korea's energy and chemical giant, OCI Co., in a series A financing, the firm is expecting another investment of $3.5 million in the coming weeks. Read More
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis. Read More
A subsidiary of Tokyo-based Kyowa Hakko Kirin Co. Ltd. has established a subsidiary of its own through which it aims to launch Kyowa Hakko Kirin's global strategic products in Australia. The new entity is named Kyowa Kirin Australia Pty Ltd. Read More
Record-breaking financings in 2018 trickled down to almost every therapeutic area, showing in many cases double- and triple-digit percent increases of funds flowing into biopharma companies working on everything from cell and gene therapies to cancer immunotherapies and microbiome therapeutics. Read More
